Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diamide SCHEMBL13680778 | 1.00 | TSHR (1.00) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL39340 | 1.00 | TSHR (1.00) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL1681704 | 0.96 | TSHR (0.93) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL3793192 | 0.96 | TSHR (0.93) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL2299006 | 0.96 | TSHR (0.93) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL8186446 | 0.96 | TSHR (0.93) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL2036888 | 0.96 | TSHR (0.93) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL1772314 | 0.96 | TSHR (0.93) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL9634763 | 0.96 | TSHR (0.93) | TSHRALDH1A1NFKB1THPOHSD17B10 | |
| Diamide SCHEMBL293153 | 0.90 | TSHR (0.81) | TSHRALDH1A1NFKB1THPOHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1671 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086923-A1 | PREPARATION METHOD FOR OLIGONUCLEOTIDE ANALOG | 福建盛迪医药有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20250361258-A1 | PROCESSES FOR MAKING PRMT5 INHIBITORS | PRELUDE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | claimed |
| CN-120035598-A | Method for preparing PRMT5 inhibitor | 普莱鲁德疗法股份有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-111615400-B | Accurate glycoconjugates as therapeutic tools | 科纳克斯资本 | 2025-05-02 | — | — | CN | claimed |
| EP-4540261-A1 | PROCESSES FOR MAKING PRMT5 INHIBITORS | Prelude Therapeutics Incorporated (US) | 2025-04-23 | — | — | EP | claimed |
| CN-119751479-A | Edison (R) sarban Synthesis method of intermediate | 沧州那瑞化学科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2025070241-A1 | COMPOUND OR SALT THEREOF, AND METHOD FOR PRODUCING THE SAME | 藤本化学製品株式会社 | 2025-04-03 | — | — | WO | claimed |
| EP-4516862-A1 | AQUEOUS COATING COMPOSITION, COATING OBTAINED FROM THE COATING COMPOSITION, SUBSTRATE CONTAINING THE COATING AND THE USE OF THE AQUEOUS COATING COMPOSITION | DAW SE (DE) | 2025-03-05 | — | — | EP | claimed |
| EP-4504736-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | Nuvalent, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| CN-119143783-A | Preparation method and application of edoxaban intermediate | 沧州那瑞化学科技有限公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2022150924-A1 | PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL | KORANEX CAPITAL (CA) | 2022-07-21 | — | — | WO | claimed |
| WO-2022125735-A1 | PROCESSES FOR MAKING PRMT5 INHIBITORS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-06-16 | — | — | WO | claimed |
| US-20220056008-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | CRYSTAL PHARMA, S.A.U. (ES) | 2022-02-24 | — | — | US | claimed |
| EP-1381633-B9 | SYNTHESIS OF VINYL POLYMERS BY CONTROLLED RADICAL POLYMERIZATION | PPG IND OHIO INC (US) | 2010-03-31 | — | — | EP | claimed |
| EP-1381633-B1 | SYNTHESIS OF VINYL POLYMERS BY CONTROLLED RADICAL POLYMERIZATION | PPG IND OHIO INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-7459552-B2 | Method for producing cyclic diamine derivative or salt thereof | KOWA CO., LTD. (JP) | 2008-12-02 | — | — | US | claimed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | claimed |
| EP-0981959-B1 | Stable 3-isothiazolone compositions | ROHM & HAAS (US) | 2002-10-30 | — | — | EP | claimed |
| US-6153633-A | Stable 3-isothiazolone compositions | ROHM AND HAAS COMPANY (US) | 2000-11-28 | — | — | US | claimed |
| EP-0981959-A1 | Stable 3-isothiazolone compositions | ROHM AND HAAS COMPANY (US) | 2000-03-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361258-A1 | PROCESSES FOR MAKING PRMT5 INHIBITORS | PRMT1, PRMT5, PRMT6 | TSHR 3431/4885ALDH1A1 1309/4885NFKB1 1313/4885 |
| US-20220056008-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | VAT1, VPS51, VMP1 | TSHR 4621/4885ALDH1A1 784/4885NFKB1 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.